> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA, Switzerland Recognizing Each Other's Inspections
- URL: https://www.fdaweb.com/fda-switzerland-recognizing-each-others-inspections/
- Published: 2023-07-28T12:00:00.000Z
- Updated: 2026-09-14T18:47:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154978

FDA and Switzerland 7/27 have entered into a mutual recognition agreement (MRA) where each regulatory agency can rely on the other’s factual findings from a good manufacturing practice (GMP) inspection of a pharmaceutical manufacturing facility. The regulatory agencies signed the agreement 1/12, but it was contingent on FDA determining that Swissmedic is capable of conducting inspections that meet U.S. requirements, and Swissmedic had made a similar determination with respect to FDA. “Both agencies have now completed those determinations based on the criteria and procedures outlined in the MRA and recognized each other under the MRA,” an [FDA notice](https://www.fda.gov/media/170595/download?attachment=&utm%5Fmedium=email&utm%5Fsource=govdelivery) says.

In addition to covering GMP inspections of facilities making human drugs, the MRA covers veterinary drugs. “MRAs are also in effect with the European Union and the United Kingdom,” the agency says. “MRAs are an effective tool in today’s global pharmaceutical market, allowing the FDA to work more efficiently and maximize its resources. Over 250 pharmaceutical companies are based in Switzerland, ranging from start-ups all the way to multinationals, according to Swissmedic, which has issued manufacturing licenses to approximately 370 sites across the country.

“Sharing information will help the FDA and Swissmedic avoid the duplication of drug inspections, lower inspection costs and enable regulators to devote more resources to other parts of the world.”